Received Sep 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE) | SANOFI PASTEUR | 1 | UT8792LA | OT |
patient is pregnant with no reported adverse event; Initial information received on 11-Sep-2025 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 33 years old pregnant female patient who was exposed to Influenza Usp Trival A-B Subvirion Vaccine [Fluzone] in context of patient is pregnant with no reported adverse event. Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported patient is pregnant with no reported adverse event occurred at 7 weeks of pregnancy and the patient was exposed to Influenza Usp Trival A-B Subvirion Vaccine at 7 weeks of pregnancy, during first pregnancy trimester for Influenza Usp Trival A-B Subvirion Vaccine. The date of last menstrual period was reported as 25-Jul-2025. The estimated due date is 01-May-2026. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies. On 11-Sep-2025, the pregnant patient received an unknown dose (dose 1) of suspect Influenza Usp Trival A-B Subvirion Vaccine, Suspension for injection (Lot UT8792LA, expiry date and strength not reported) via intramuscular route in unknown administration site for prophylactic vaccination (Immunisation) and with no reported adverse event (maternal exposure during pregnancy). Action taken was not applicable. Additionally, at time of reporting, the pregnancy is still ongoing.